Biosig Technologies (NASDAQ:STEX) and ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Analysis

ReShape Lifesciences (OTCMKTS:RSLSD) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for ReShape Lifesciences and Biosig Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	0.00
Biosig Technologies	1	0	0	0	1.00

Given ReShape Lifesciences’ higher probable upside, research analysts clearly believe ReShape Lifesciences is more favorable than Biosig Technologies.

Institutional and Insider Ownership

7.2% of Biosig Technologies shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ReShape Lifesciences and Biosig Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Biosig Technologies	N/A	N/A	-64.96%

Earnings and Valuation

This table compares ReShape Lifesciences and Biosig Technologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A
Biosig Technologies	$13,000.00	16,616.09	-$10.33 million	($1.35)	-0.90

Biosig Technologies has lower revenue, but higher earnings than ReShape Lifesciences.

Volatility and Risk

ReShape Lifesciences has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Biosig Technologies has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500.

Summary

Biosig Technologies beats ReShape Lifesciences on 6 of the 10 factors compared between the two stocks.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.